Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
14 Total results for product and free and sample content found
In Vivo
By Rachel Laing, Alessia Deglincerti, Mark Ratner 27 Nov 2020
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.
Scrip
By Kevin Grogan 27 Nov 2020
As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.
Topic Alzheimer's Disease
Scrip
By Joseph Haas 27 Nov 2020
The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.
Topic Alzheimer's Disease
Scrip
By Mandy Jackson 22 Aug 2018
Further new data for the Biogen and Eisai drug BAN2401 appear to show it significantly reduces amyloid plaque and cognitive declines in Alzheimer's patients in a dose-dependent manner, but a lot of questions – and skepticism about the data – remain.
Topic Alzheimer's Disease Clinical Trials Research & Development
Pink Sheet
By Brenda Sandburg 15 May 2018
US FDA revises draft guidance issued in 2013 to allow research targeting cognition as single endpoint and studies solely evaluating biomarkers; document offers 'potential for multiple advances,' Alzheimer's Association says.
Topic Alzheimer's Disease
Sitetrove
07 Jan 2018
November is National Alzheimer’s Disease (AD) Awareness Month. Sitetrove wants to raise awareness by going purple! This infographic offers an overview of the current global investigator landscape and how AD trial experience has shifted over the last 10 years
Topic Alzheimer's Disease
Biomedtracker
26 Oct 2017
In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.
Biomedtracker
16 Jul 2017
In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.
Pink Sheet
By Sten Stovall 04 Apr 2017
Biogen's chief medical officer says iPhone technology should in future be used for early warning diagnosis of Alzheimer's Disease.
Topic Alzheimer's Disease
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
